Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CEVA 101

Next Previous
Drug Profile

CEVA 101

Alternative Names: Autologous BMMNCs - Cellvation/University of Texas Health Science Center, Houston; Autologous bone marrow mononuclear cells - Cellvation/University of Texas Health Science Center at Houston; Autologous bone marrow-derived stem cells – Cellvation/University of Texas Health Science Center at Houston; CEVA101

Latest Information Update: 08 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas Health Science Center at Houston
  • Developer Cellvation; National Institute of Neurological Disorders and Stroke; University of Texas Health Science Center at Houston
  • Class Cell therapies; Neuroprotectants
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain injuries

Most Recent Events

  • 08 Dec 2022 CEVA 101 is still in phase II development in Brain injuries (In adults) in USA (IV) (NCT02525432) (Cellvation pipeline, November 2022)
  • 08 Dec 2022 CEVA 101 is still in phase II development in Brain injury (In adolescents, In children) in the US (NCT01851083) (Cellvation pipeline, November 2022)
  • 12 Oct 2020 The University of Texas Health Science Center at Houston completes a phase II trial in Traumatic brain injury in the US (NCT01851083)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top